Tipifarnib (Janssen Pharmaceutica).

  • Peter Norman
  • Published 2002 in Current opinion in investigational drugs

Abstract

Janssen is developing tipifarnib (formerly known as R-1 15777), an inhibitor of RAS farnesylation, for the potential treatment of neoplasia [287030], [289610]. Janssen commenced clinical trials in the US, in conjunction with the National Cancer Institute, in April 1997 [287030], [289610], and by May 1999, phase II trials in patients with advanced non-small… (More)

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.